Rolapitant Hydrochloride Patent Expiration
Rolapitant Hydrochloride is Used for prevention of delayed nausea and vomiting associated with emetogenic cancer chemotherapy. It was first introduced by Tersera Therapeutics Llc
Rolapitant Hydrochloride Patents
Given below is the list of patents protecting Rolapitant Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Varubi | US9101615 | Intravenous formulations of neurokinin-1 antagonists | Jul 14, 2032 | Tersera |
| Varubi | US8361500 | Tablet formulations containing 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one salts and tablets made therefrom | Oct 09, 2029 | Tersera |
| Varubi | US8470842 | Hydrochloride salts of 8-[{1-(3,5-Bis-trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor | Jan 18, 2029 | Tersera |
| Varubi | US7049320 | NK1 antagonists | Aug 19, 2028 | Tersera |
| Varubi | US7563801 | Pharmaceutical formulations: salts of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same | Apr 04, 2027 | Tersera |
| Varubi | US7981905 | Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-Ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same | Apr 04, 2027 | Tersera |
| Varubi | US8178550 | Hydrochloride salts of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy)-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor | Apr 04, 2027 | Tersera |
| Varubi | US8404702 | Pharmaceutical formulations:salts of 8-[1-3,5-bis-(trifluoromethyl)phenyl)-ethoxymethyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same | Apr 04, 2027 | Tersera |
| Varubi | US7049230 | Method of forming a contact plug in a semiconductor device |
Dec 08, 2023
(Expired) | Tersera |
| Varubi | US8796299 | NK1 antagonists |
Dec 17, 2022
(Expired) | Tersera |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Rolapitant Hydrochloride's patents.
Latest Legal Activities on Rolapitant Hydrochloride's Patents
Given below is the list recent legal activities going on the following patents of Rolapitant Hydrochloride.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 15 Nov, 2023 | US8178550 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 13 Feb, 2023 | US9101615 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 19 Jan, 2023 | US7981905 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 07 Feb, 2022 | US8796299 |
| Patent Term Extension Certificate Critical | 19 Nov, 2021 | US7049320 |
| Notice of Final Determination -Eligible | 04 Mar, 2021 | US7049320 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 30 Sep, 2020 | US8470842 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 30 Sep, 2020 | US7563801 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 28 Sep, 2020 | US8404702 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 29 Jul, 2020 | US8361500 |
Rolapitant Hydrochloride's Family Patents
